Title:
COMPOSITIONS AND METHODS RELATING TO ATP/P2X7R SIGNALING INHIBITION
Document Type and Number:
WIPO Patent Application WO/2023/158601
Kind Code:
A3
Abstract:
Described herein are compositions, combinations, and methods relating to treating or preventing immune-related diseases, type 1 diabetes, transplant rejection, or lung fibrosis, or slowing or delaying aging processes or extending lifespan in a subject, including subjects with rs3751143.
Inventors:
FIORINA PAOLO (US)
NASR MOUFIDA BEN (US)
NASR MOUFIDA BEN (US)
Application Number:
PCT/US2023/012877
Publication Date:
October 26, 2023
Filing Date:
February 13, 2023
Export Citation:
Assignee:
CHILDRENS MEDICAL CT CORP (US)
International Classes:
C07C15/12; A61K31/33; A61P3/10; A61P11/00; A61P37/00
Foreign References:
| US20200062693A1 | 2020-02-27 | |||
| US20030013704A1 | 2003-01-16 | |||
| US20190184027A1 | 2019-06-20 | |||
| US20110229411A1 | 2011-09-22 |
Other References:
DATABASE PubChem PUBCHEM : " 877EF4AD41B3BE1AF07CAB1888D181D1", XP093104167
FRANCESCA D’ADDIO, ANDREA VERGANI,2 LUCIANO POTENA,3 ANNA MAESTRONI,1 VERA USUELLI,2 MOUFIDA BEN NASR,1,2 ROBERTO BASSI,2 SAR: "P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 128, no. 8, 1 August 2018 (2018-08-01), pages 3490 - 3503, XP093104160
FRANCESCA D’ADDIO, ANDREA VERGANI,2 LUCIANO POTENA,3 ANNA MAESTRONI,1 VERA USUELLI,2 MOUFIDA BEN NASR,1,2 ROBERTO BASSI,2 SAR: "P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 128, no. 8, 1 August 2018 (2018-08-01), pages 3490 - 3503, XP093104160
Attorney, Agent or Firm:
KLING, Nicole D. et al. (US)
Download PDF:
Previous Patent: INTEGRATED PARTIAL OXIDATION AND ELECTROLYSIS PROCESS
Next Patent: FUNGICIDAL HALOMETHYL KETONES, HYDRATES AND ENOL ETHERS
Next Patent: FUNGICIDAL HALOMETHYL KETONES, HYDRATES AND ENOL ETHERS